Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CELL-PROLIFERATION AS A PREDICTOR OF RESPONSE TO CHEMOTHERAPY IN METASTATIC BREAST-CANCER - A PROSPECTIVE-STUDY
Autore:
AMADORI D; VOLPI A; MALTONI R; NANNI O; AMADUCCI L; AMADORI A; GIUNCHI DC; VIO A; SARAGONI A; SILVESTRINI R;
Indirizzi:
PIERANTONI HOSP,DEPT MED ONCOL,VIA FORLANINI 34 I-47100 FORLI ITALY IST ONCOL ROMAGNOLO FORLI ITALY UNIV BOLOGNA,DEPT OBSTET & GYNECOL,REPROD MED UNIT I-40138 BOLOGNA ITALY MORGAGNI HOSP,DEPT GEN SURG FORLI ITALY PIERANTONI HOSP,DEPT PATHOL FORLI ITALY IST NAZL STUDIO & CURA TUMORI,DEPT EXPT ONCOL C I-20133 MILAN ITALY
Titolo Testata:
Breast cancer research and treatment
fascicolo: 1, volume: 43, anno: 1997,
pagine: 7 - 14
SICI:
0167-6806(1997)43:1<7:CAAPOR>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
THYMIDINE LABELING INDEX; PROGNOSTIC FACTORS; KINETICS; DRUG;
Keywords:
CELL PROLIFERATION; CHEMOTHERAPY; METASTATIC BREAST CANCER; PREDICTIVE VALUE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
D. Amadori et al., "CELL-PROLIFERATION AS A PREDICTOR OF RESPONSE TO CHEMOTHERAPY IN METASTATIC BREAST-CANCER - A PROSPECTIVE-STUDY", Breast cancer research and treatment, 43(1), 1997, pp. 7-14

Abstract

Many biologic prognostic markers are available for patients with breast cancer, and considerable interest has been devoted to confirm preliminary evidence of their role as indicators of treatment response. It remains to be assessed whether such markers are predictors of responseonly to first-line or also to successive therapies. Proliferative activity, defined by the H-3-thymidine labeling index (TLI), was determined on the primary lesion from 76 patients at time of first diagnosis. At relapse, patients underwent chemotherapy as absolute (48 cases) or relative (28 cases) first-line treatment, and their clinical response was analyzed in relation to the TLI of the primary lesion. The objective clinical response was significantly higher for rapidly (47%; CL, 33-61%) than for slowly proliferating tumors (15%; CL, 1-29%). These findings held true also when adjusted for metastatic site, previous treatment, chemotherapy regimen administered, and hormone receptor status. However, the direct relation between cell proliferation and benefit from chemotherapy held true only when such a treatment was used as an absolute first-line approach. Cell proliferation of primary lesions represents a consistent indicator of response to chemotherapy over time. Previously administered regimens, at least hormone therapy, could alterthe proliferation-related chemosensitivity profile of individual tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 04:54:57